Background and Aims: Clinical application of CD8 response measured by the newer interferon gamma release assay, QuantiFERON-TB Gold-Plus (QFT-Plus), remained to be investigated.
107 active TB) were included. The concordance rate of QFT-GIT and QFT-Plus was high (n = 278, 88.5%). While TB1 and TB2 response were not different between active TB and LTBI (TB1, active TB vs LTBI: 1.79 AE 2.80 IU/ml vs 1.99 AE 2.26 IU/ml, P = 0.581; TB2, active TB vs LTBI: 2.29 AE 3.15 IU/ml vs 2.03 AE 2.25 IU/ml, P = 0.507), CD8 response was higher in active TB than LTBI (active TB vs LTBI: 0.49 AE 1.57 IU/ml vs 0.04 AE 1.53 IU/ml, P = 0.041). CD8 response was also higher in active TB than healthy contacts (active TB vs healthy contacts: 0.49 AE 1.57 IU/ml vs 0.01 AE 0.19 IU/ml, P = 0.002). For CD8 response >2 IU/ml (n = 12), 9 (75%) were active TB and 3 (25%) were LTBI. The results were also similar if the diagnosis LTBI was made by positivity of QFT-GIT rather than QFT-Plus.
Conclusion:
This study revealed CD8 response by QFT-Plus was different between healthy contacts, LTBI as well as active TB and holds potential as a novel biomarker. Methods: EBM research were undertaken on PubMed using the search terms fibrinogen, remodeling, TGFβ-1, AE-COPD, airway hyperresponsiveness, chronic rhinosinusitis (CRS) and peripheral eosinophil. Meta-analysis and systematic review or RCT were initiated and also limit papers published between Jul 2012 to May 2018. Oxford center for EBM 2011 edition was referenced for level of evidence (LoE).
Results: TGFβ1 polymorphism rs1982073 was associated with decreased risk of COPD in Caucasians (OR 0.79) (P = 0.038) but not in Asians (Liao N 2017; LoE [1] ). COPD markers such as soluble urokinasetype plasminogen activator receptor, CRP and fibrinogen decreased after treatment, and only suPAR (P = 0.002) and fibrinogen(P = 0.014) predicted AE-COPD (Gumus A 2015; LoE[3] ). COPD associated bronchiectasis showed significantly more severe in w/CRS than in s/CRS (P = 0.034) and the eosinophils% and the levels of IL-6 and MMP-9 in sputum were increased (Yang X 2017; LoE [3] ). CRP elevated in AE-COPD compared to the control but IL-6, TNF-α still variated (Chen YW 2016; LoE [1] ). The use of Anti-IgE, anti-IL-5 and anti-IL-4/anti-IL-13 therapy in CRS with nasal polyp (CRSwNP) were effective in reducing total nasal endoscopic polyp score, nasal airflow, olfaction and Th-2 associated biomarkers (Tsetsos N. 2018; LoE[1]).
Our study highlights on difference of the roles of ethnicity, TGFβ-1 and fibrinogen. Therapeutic interest by monoclonal antibody is arising soon. 
